Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib, Gemcitabine, and Nab-paclitaxel in Peri-operative Pancreatic Cancer
NCT05908747Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started May 2023; status: completed.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05908747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908747.